サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1617120

研究用抗体・試薬の2030年までの市場予測：技術、用途、エンドユーザー、地域別の世界分析

Research Antibodies and Reagents Market Forecasts to 2030 - Global Analysis By Technology, Application, End User and By Geography

出版日
ページ情報
英文 200+ Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
研究用抗体・試薬の2030年までの市場予測：技術、用途、エンドユーザー、地域別の世界分析
出版日: 2024年12月11日
発行: Stratistics Market Research Consulting
ページ情報: 英文 200+ Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

Stratistics MRCによると、世界の研究用抗体・試薬市場は2024年に128億3,000万米ドルを占め、予測期間中にCAGR 8.7％で成長し、2030年には211億6,000万米ドルに達すると予測されています。

調査用抗体と試薬は、主に分子生物学、免疫学、生化学の分野における科学実験に不可欠なツールです。免疫系によって産生されるタンパク質である抗体は、特異的な抗原に結合するように特別に設計されており、様々な生物学的サンプル中のタンパク質やその他の分子を検出、同定、定量するのに非常に有用です。一方、調査試薬とは、実験に使用される緩衝液、酵素、プライマー、その他の化学物質など、実験手順を促進または強化する幅広い物質を指します。これらの試薬は、反応に必要な化学的環境や生物学的成分を提供することで、実験の精度と信頼性を最適化するのに役立ちます。

CBRE Researchによると、米国のライフサイエンス企業による研究開発費は過去5年間で40%増加し、2021年には1,540億米ドル近くに達します。

個別化医療への需要の高まり

個人の遺伝的体質、ライフスタイル、特定の疾患特性に基づいて治療を調整する個別化医療には、正確で的を絞った診断ツールが必要です。特定のタンパク質やバイオマーカーを検出するために不可欠な調査用抗体や、様々な実験手順を可能にする試薬は、個別化治療の進展に重要な役割を果たしています。これらの抗体や試薬は、個別化医療に不可欠な要素である遺伝子検査、バイオマーカー探索、薬剤開発の開発に活用されています。分子レベルで病気のメカニズムを正確に捉える能力は、より効果的で副作用の少ない治療を開発する上で極めて重要です。

製品の高コスト

研究用抗体や試薬のコストが高いことは、特に免疫学、バイオテクノロジー、医薬品開発などの分野において、科学の進歩にとって大きな障壁となっています。診断、タンパク質分析、細胞研究などの実験に使用されるこれらの必須ツールは、生産量の制限、品質管理基準、原材料費などの要因により、しばしば法外に高価です。多くの学術機関、小規模研究所、新進研究者は予算の制約に直面しており、必要な抗体や試薬を入手することが困難です。その結果、プロジェクトの遅延、実験範囲の制限、科学的進歩の鈍化を招いています。

がん研究への投資の増加

がん研究に対する投資の増加は、研究用抗体や試薬の開発を大きく前進させる原動力となっており、これらはがんを分子レベルで理解し標的とするために不可欠なツールです。がん研究が進化を続ける中、資金援助により科学者たちはより特異的で感度が高く、多様な抗体を開発し、がんマーカーの検出や腫瘍の進行を追跡する能力を高めています。これらの試薬は基礎研究と臨床の双方において重要であり、がん生物学のより深い理解、新たな治療標的の同定、診断法の改善を促進しています。免疫療法と個別化医療への注目の高まりは、健康な組織へのダメージを最小限に抑えながら特定のがん細胞を標的にできる高品質の抗体への需要をさらに高めています。

品質と特異性の問題

研究用抗体と試薬市場は、品質と特異性の問題に関連する大きな課題に直面しており、科学的研究における有効性を妨げています。タンパク質の検出や分析に不可欠な抗体は、製造工程のばらつきや不十分なバリデーションにより、しばしば性能のばらつきに悩まされます。その結果、再現性が悪くなり、抗体が意図しないターゲットに結合してしまい、不正確な結果につながることがあります。試薬の処方が標準化されていないため、実験プロトコールが複雑になり、研究者は異なる研究室間で結果を再現することが困難になる可能性があります。

COVID-19の影響：

COVID-19の大流行は調査用抗体・試薬市場に大きな影響を与え、サプライチェーン、研究の優先順位、製造プロセスを混乱させました。パンデミックの最盛期には、多くの研究所や研究機関がウイルスの研究に重点を移したため、COVID-19の検出と治療に特化した抗体、試薬、診断ツールの需要が増加しました。このような状況下、多くの研究者は代替試薬を調達したり、研究プロトコルを変更したりして適応せざるを得なかった。このような課題にもかかわらず、パンデミックは抗体や試薬開発、特にウイルス検出やワクチン研究の技術革新を加速させました。

予測期間中、フローサイトメトリー分野が最大となる見込み

予測期間中、フローサイトメトリー部門が最大のシェアを占めると予想されます。フローサイトメトリーは、免疫学、細胞生物学、診断学で使用される強力なツールであり、物理的・化学的特性に基づいて細胞を分析・選別します。フローサイトメトリー技術の精度と信頼性を向上させるためには、研究用抗体と試薬の強化が不可欠です。高度に特異的で最適化された抗体を開発することにより、研究者は広範囲の細胞表面マーカーや細胞内タンパク質を標的とすることができ、複雑な生物学的プロセスの研究が容易になります。蛍光コンジュゲート、バッファー、検出システムなどの試薬の革新は、フローサイトメトリーの感度、分解能、精度をさらに高める。

予測期間中にCAGRが最も高くなると予測されるのは医薬品開発セグメントです。

医薬品開発セグメントは予測期間中に急成長すると予測されます。医薬品開発分野では、新しい治療薬の発見と開発を加速するために、研究用抗体や試薬の強化にますます力を入れるようになっています。これらの抗体や試薬は、疾患の根本的なメカニズムの解明、潜在的な創薬標的の同定、治療薬候補の検証において重要な役割を果たしています。これらのツールの品質、特異性、信頼性を向上させることで、研究者はより正確で再現性の高いデータを作成できるようになり、創薬の進展に不可欠なものとなります。研究用抗体の強化は、正確なバイオマーカー検出、細胞シグナル伝達経路解析、体外診断アプリケーションに役立ちます。

最大のシェアを占める地域

北米地域は、予測期間を通じて同市場で最大のシェアを占めるものと思われます。バイオテクノロジー、医薬品、個別化医療の継続的な進歩に伴い、高品質の抗体と試薬の需要が急増しています。これらのツールは、特にがん、自己免疫疾患、感染症における標的療法、バイオマーカー同定、診断の開発に不可欠です。北米の研究者は、CRISPRや遺伝子編集といった最先端の技術を活用しており、これらは特殊な試薬や抗体に大きく依存しています。さらに、製薬会社や学術機関による研究開発への投資の増加が、この地域の需要をさらに加速させています。

CAGRが最も高い地域：

欧州地域は、予測期間中に最も高いCAGRを示すと推定されています。学術機関、研究機関、バイオテクノロジー企業間の連携を促進することで、欧州はライフサイエンスにおける最先端開発の拠点となっています。こうしたパートナーシップにより、専門知識、リソース、技術の共有が可能になり、高品質の抗体や試薬の発見と最適化が加速しています。さらに、世界の業界リーダーとの合弁事業や協力関係により、最新技術や規制に関する見識へのアクセスが確保され、より具体的で効果的な研究ツールの開発が促進されます。その結果、欧州の研究者はより広範な専門製品の恩恵を受け、正確でインパクトのある実験を実施する能力を高めています。

無料のカスタマイズサービス：

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

  • 企業プロファイル
    • 追加市場プレイヤーの包括的プロファイリング（3社まで）
    • 主要企業のSWOT分析（3社まで）
  • 地域セグメンテーション
    • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
  • 競合ベンチマーキング
    • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

  • 概要
  • ステークホルダー
  • 調査範囲
  • 調査手法
    • データマイニング
    • データ分析
    • データ検証
    • 調査アプローチ
  • 調査情報源
    • 1次調査情報源
    • 2次調査情報源
    • 前提条件

第3章 市場動向分析

  • ドライバー
  • 抑制要因
  • 機会
  • 脅威
  • 技術分析
  • 用途分析
  • エンドユーザー分析
  • 新興市場
  • COVID-19の影響

第4章 ポーターのファイブフォース分析

  • 供給企業の交渉力
  • 買い手の交渉力
  • 代替品の脅威
  • 新規参入業者の脅威
  • 競争企業間の敵対関係

第5章 世界の研究用抗体・試薬市場：技術別

  • フローサイトメトリー
  • 免疫沈降法
  • ウエスタンブロッティング
  • マルチプレックス免疫吸着アッセイ
  • 酵素免疫測定法
  • その他の技術

第6章 世界の研究用抗体・試薬市場：用途別

  • 医薬品開発
  • プロテオミクス
  • ゲノミクス

第7章 世界の研究用抗体・試薬市場：エンドユーザー別

  • 製薬およびバイオテクノロジー産業
  • 学術研究機関
  • 契約研究機関

第8章 世界の研究用抗体・試薬市場：地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン
    • その他欧州
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • ニュージーランド
    • 韓国
    • その他アジア太平洋
  • 南米
    • アルゼンチン
    • ブラジル
    • チリ
    • その他南米
  • 中東・アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • カタール
    • 南アフリカ
    • その他中東とアフリカ

第9章 主な発展

  • 契約、パートナーシップ、コラボレーション、合弁事業
  • 買収と合併
  • 新製品発売
  • 事業拡大
  • その他の主要戦略

第10章 企業プロファイリング

  • Abcam Limited
  • Agilent Technologies, Inc
  • Bio-Rad Laboratories, Inc
  • F. Hoffmann-La Roche AG
  • GE Healthcare Life Sciences
  • Merck Group
  • OriGene Technologies
  • PerkinElmer
  • Promega Corporation
  • SAB Biotherapeutics
  • Santa Cruz Biotechnology
  • Tecan Group
  • Thermo Fisher Scientific
  • Eppendorf AG
  • Lonza Group
図表

List of Tables

  • Table 1 Global Research Antibodies and Reagents Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Research Antibodies and Reagents Market Outlook, By Technology (2022-2030) ($MN)
  • Table 3 Global Research Antibodies and Reagents Market Outlook, By Flow Cytometry (2022-2030) ($MN)
  • Table 4 Global Research Antibodies and Reagents Market Outlook, By Immunoprecipitation (2022-2030) ($MN)
  • Table 5 Global Research Antibodies and Reagents Market Outlook, By Western Blotting (2022-2030) ($MN)
  • Table 6 Global Research Antibodies and Reagents Market Outlook, By Multiplex Immunosorbent Assay (2022-2030) ($MN)
  • Table 7 Global Research Antibodies and Reagents Market Outlook, By Enzyme-Linked Immunosorbent Assay (2022-2030) ($MN)
  • Table 8 Global Research Antibodies and Reagents Market Outlook, By Other Technologies (2022-2030) ($MN)
  • Table 9 Global Research Antibodies and Reagents Market Outlook, By Application (2022-2030) ($MN)
  • Table 10 Global Research Antibodies and Reagents Market Outlook, By Drug Development (2022-2030) ($MN)
  • Table 11 Global Research Antibodies and Reagents Market Outlook, By Proteomics (2022-2030) ($MN)
  • Table 12 Global Research Antibodies and Reagents Market Outlook, By Genomics (2022-2030) ($MN)
  • Table 13 Global Research Antibodies and Reagents Market Outlook, By End User (2022-2030) ($MN)
  • Table 14 Global Research Antibodies and Reagents Market Outlook, By Pharmaceutical and Biotechnologies Industries (2022-2030) ($MN)
  • Table 15 Global Research Antibodies and Reagents Market Outlook, By Academic and Research Institutions (2022-2030) ($MN)
  • Table 16 Global Research Antibodies and Reagents Market Outlook, By Contract Research Organizations (2022-2030) ($MN)
  • Table 17 North America Research Antibodies and Reagents Market Outlook, By Country (2022-2030) ($MN)
  • Table 18 North America Research Antibodies and Reagents Market Outlook, By Technology (2022-2030) ($MN)
  • Table 19 North America Research Antibodies and Reagents Market Outlook, By Flow Cytometry (2022-2030) ($MN)
  • Table 20 North America Research Antibodies and Reagents Market Outlook, By Immunoprecipitation (2022-2030) ($MN)
  • Table 21 North America Research Antibodies and Reagents Market Outlook, By Western Blotting (2022-2030) ($MN)
  • Table 22 North America Research Antibodies and Reagents Market Outlook, By Multiplex Immunosorbent Assay (2022-2030) ($MN)
  • Table 23 North America Research Antibodies and Reagents Market Outlook, By Enzyme-Linked Immunosorbent Assay (2022-2030) ($MN)
  • Table 24 North America Research Antibodies and Reagents Market Outlook, By Other Technologies (2022-2030) ($MN)
  • Table 25 North America Research Antibodies and Reagents Market Outlook, By Application (2022-2030) ($MN)
  • Table 26 North America Research Antibodies and Reagents Market Outlook, By Drug Development (2022-2030) ($MN)
  • Table 27 North America Research Antibodies and Reagents Market Outlook, By Proteomics (2022-2030) ($MN)
  • Table 28 North America Research Antibodies and Reagents Market Outlook, By Genomics (2022-2030) ($MN)
  • Table 29 North America Research Antibodies and Reagents Market Outlook, By End User (2022-2030) ($MN)
  • Table 30 North America Research Antibodies and Reagents Market Outlook, By Pharmaceutical and Biotechnologies Industries (2022-2030) ($MN)
  • Table 31 North America Research Antibodies and Reagents Market Outlook, By Academic and Research Institutions (2022-2030) ($MN)
  • Table 32 North America Research Antibodies and Reagents Market Outlook, By Contract Research Organizations (2022-2030) ($MN)
  • Table 33 Europe Research Antibodies and Reagents Market Outlook, By Country (2022-2030) ($MN)
  • Table 34 Europe Research Antibodies and Reagents Market Outlook, By Technology (2022-2030) ($MN)
  • Table 35 Europe Research Antibodies and Reagents Market Outlook, By Flow Cytometry (2022-2030) ($MN)
  • Table 36 Europe Research Antibodies and Reagents Market Outlook, By Immunoprecipitation (2022-2030) ($MN)
  • Table 37 Europe Research Antibodies and Reagents Market Outlook, By Western Blotting (2022-2030) ($MN)
  • Table 38 Europe Research Antibodies and Reagents Market Outlook, By Multiplex Immunosorbent Assay (2022-2030) ($MN)
  • Table 39 Europe Research Antibodies and Reagents Market Outlook, By Enzyme-Linked Immunosorbent Assay (2022-2030) ($MN)
  • Table 40 Europe Research Antibodies and Reagents Market Outlook, By Other Technologies (2022-2030) ($MN)
  • Table 41 Europe Research Antibodies and Reagents Market Outlook, By Application (2022-2030) ($MN)
  • Table 42 Europe Research Antibodies and Reagents Market Outlook, By Drug Development (2022-2030) ($MN)
  • Table 43 Europe Research Antibodies and Reagents Market Outlook, By Proteomics (2022-2030) ($MN)
  • Table 44 Europe Research Antibodies and Reagents Market Outlook, By Genomics (2022-2030) ($MN)
  • Table 45 Europe Research Antibodies and Reagents Market Outlook, By End User (2022-2030) ($MN)
  • Table 46 Europe Research Antibodies and Reagents Market Outlook, By Pharmaceutical and Biotechnologies Industries (2022-2030) ($MN)
  • Table 47 Europe Research Antibodies and Reagents Market Outlook, By Academic and Research Institutions (2022-2030) ($MN)
  • Table 48 Europe Research Antibodies and Reagents Market Outlook, By Contract Research Organizations (2022-2030) ($MN)
  • Table 49 Asia Pacific Research Antibodies and Reagents Market Outlook, By Country (2022-2030) ($MN)
  • Table 50 Asia Pacific Research Antibodies and Reagents Market Outlook, By Technology (2022-2030) ($MN)
  • Table 51 Asia Pacific Research Antibodies and Reagents Market Outlook, By Flow Cytometry (2022-2030) ($MN)
  • Table 52 Asia Pacific Research Antibodies and Reagents Market Outlook, By Immunoprecipitation (2022-2030) ($MN)
  • Table 53 Asia Pacific Research Antibodies and Reagents Market Outlook, By Western Blotting (2022-2030) ($MN)
  • Table 54 Asia Pacific Research Antibodies and Reagents Market Outlook, By Multiplex Immunosorbent Assay (2022-2030) ($MN)
  • Table 55 Asia Pacific Research Antibodies and Reagents Market Outlook, By Enzyme-Linked Immunosorbent Assay (2022-2030) ($MN)
  • Table 56 Asia Pacific Research Antibodies and Reagents Market Outlook, By Other Technologies (2022-2030) ($MN)
  • Table 57 Asia Pacific Research Antibodies and Reagents Market Outlook, By Application (2022-2030) ($MN)
  • Table 58 Asia Pacific Research Antibodies and Reagents Market Outlook, By Drug Development (2022-2030) ($MN)
  • Table 59 Asia Pacific Research Antibodies and Reagents Market Outlook, By Proteomics (2022-2030) ($MN)
  • Table 60 Asia Pacific Research Antibodies and Reagents Market Outlook, By Genomics (2022-2030) ($MN)
  • Table 61 Asia Pacific Research Antibodies and Reagents Market Outlook, By End User (2022-2030) ($MN)
  • Table 62 Asia Pacific Research Antibodies and Reagents Market Outlook, By Pharmaceutical and Biotechnologies Industries (2022-2030) ($MN)
  • Table 63 Asia Pacific Research Antibodies and Reagents Market Outlook, By Academic and Research Institutions (2022-2030) ($MN)
  • Table 64 Asia Pacific Research Antibodies and Reagents Market Outlook, By Contract Research Organizations (2022-2030) ($MN)
  • Table 65 South America Research Antibodies and Reagents Market Outlook, By Country (2022-2030) ($MN)
  • Table 66 South America Research Antibodies and Reagents Market Outlook, By Technology (2022-2030) ($MN)
  • Table 67 South America Research Antibodies and Reagents Market Outlook, By Flow Cytometry (2022-2030) ($MN)
  • Table 68 South America Research Antibodies and Reagents Market Outlook, By Immunoprecipitation (2022-2030) ($MN)
  • Table 69 South America Research Antibodies and Reagents Market Outlook, By Western Blotting (2022-2030) ($MN)
  • Table 70 South America Research Antibodies and Reagents Market Outlook, By Multiplex Immunosorbent Assay (2022-2030) ($MN)
  • Table 71 South America Research Antibodies and Reagents Market Outlook, By Enzyme-Linked Immunosorbent Assay (2022-2030) ($MN)
  • Table 72 South America Research Antibodies and Reagents Market Outlook, By Other Technologies (2022-2030) ($MN)
  • Table 73 South America Research Antibodies and Reagents Market Outlook, By Application (2022-2030) ($MN)
  • Table 74 South America Research Antibodies and Reagents Market Outlook, By Drug Development (2022-2030) ($MN)
  • Table 75 South America Research Antibodies and Reagents Market Outlook, By Proteomics (2022-2030) ($MN)
  • Table 76 South America Research Antibodies and Reagents Market Outlook, By Genomics (2022-2030) ($MN)
  • Table 77 South America Research Antibodies and Reagents Market Outlook, By End User (2022-2030) ($MN)
  • Table 78 South America Research Antibodies and Reagents Market Outlook, By Pharmaceutical and Biotechnologies Industries (2022-2030) ($MN)
  • Table 79 South America Research Antibodies and Reagents Market Outlook, By Academic and Research Institutions (2022-2030) ($MN)
  • Table 80 South America Research Antibodies and Reagents Market Outlook, By Contract Research Organizations (2022-2030) ($MN)
  • Table 81 Middle East & Africa Research Antibodies and Reagents Market Outlook, By Country (2022-2030) ($MN)
  • Table 82 Middle East & Africa Research Antibodies and Reagents Market Outlook, By Technology (2022-2030) ($MN)
  • Table 83 Middle East & Africa Research Antibodies and Reagents Market Outlook, By Flow Cytometry (2022-2030) ($MN)
  • Table 84 Middle East & Africa Research Antibodies and Reagents Market Outlook, By Immunoprecipitation (2022-2030) ($MN)
  • Table 85 Middle East & Africa Research Antibodies and Reagents Market Outlook, By Western Blotting (2022-2030) ($MN)
  • Table 86 Middle East & Africa Research Antibodies and Reagents Market Outlook, By Multiplex Immunosorbent Assay (2022-2030) ($MN)
  • Table 87 Middle East & Africa Research Antibodies and Reagents Market Outlook, By Enzyme-Linked Immunosorbent Assay (2022-2030) ($MN)
  • Table 88 Middle East & Africa Research Antibodies and Reagents Market Outlook, By Other Technologies (2022-2030) ($MN)
  • Table 89 Middle East & Africa Research Antibodies and Reagents Market Outlook, By Application (2022-2030) ($MN)
  • Table 90 Middle East & Africa Research Antibodies and Reagents Market Outlook, By Drug Development (2022-2030) ($MN)
  • Table 91 Middle East & Africa Research Antibodies and Reagents Market Outlook, By Proteomics (2022-2030) ($MN)
  • Table 92 Middle East & Africa Research Antibodies and Reagents Market Outlook, By Genomics (2022-2030) ($MN)
  • Table 93 Middle East & Africa Research Antibodies and Reagents Market Outlook, By End User (2022-2030) ($MN)
  • Table 94 Middle East & Africa Research Antibodies and Reagents Market Outlook, By Pharmaceutical and Biotechnologies Industries (2022-2030) ($MN)
  • Table 95 Middle East & Africa Research Antibodies and Reagents Market Outlook, By Academic and Research Institutions (2022-2030) ($MN)
  • Table 96 Middle East & Africa Research Antibodies and Reagents Market Outlook, By Contract Research Organizations (2022-2030) ($MN)
目次
Product Code: SMRC27998

According to Stratistics MRC, the Global Research Antibodies and Reagents Market is accounted for $12.83 billion in 2024 and is expected to reach $21.16 billion by 2030 growing at a CAGR of 8.7% during the forecast period. Research antibodies and reagents are essential tools in scientific experiments, primarily in the fields of molecular biology, immunology, and biochemistry. Antibodies, which are proteins produced by the immune system, are specifically designed to bind to unique antigens, making them invaluable for detecting, identifying, and quantifying proteins or other molecules in various biological samples. Research reagents, on the other hand, refer to a broad range of substances that facilitate or enhance laboratory procedures, including buffers, enzymes, primers, and other chemicals used in experiments. These reagents help optimize the accuracy and reliability of experiments by providing the necessary chemical environment or biological components for reactions to occur.

According to CBRE Research, R&D expenditures by US life sciences companies have grown by ~ 40% over the past five years to reach nearly USD 154 billion in 2021.

Market Dynamics:

Driver:

Rising demand for personalized medicine

Personalized medicine, which tailors treatments based on an individual's genetic makeup, lifestyle, and specific disease characteristics, requires precise and targeted diagnostic tools. Research antibodies, which are essential for detecting specific proteins or biomarkers, and reagents that enable various laboratory procedures, play a crucial role in advancing personalized therapies. These antibodies and reagents are utilized in the development of genetic testing, biomarker discovery, and drug development, which are integral components of personalized medicine. The ability to accurately target disease mechanisms at a molecular level is pivotal in developing treatments that are more effective and have fewer side effects.

Restraint:

High cost of products

The high cost of research antibodies and reagents is a significant barrier to scientific progress, particularly in fields like immunology, biotechnology, and drug development. These essential tools, used for experiments such as diagnostics, protein analysis, and cell research, are often prohibitively expensive due to factors like limited production, high-quality control standards, and the cost of raw materials. Many academic institutions, small labs, and emerging researchers face budget constraints, making it difficult to access the required antibodies and reagents. This results in delayed projects, limited scope of experiments, and a slowdown in scientific advancements.

Opportunity:

Increased investment in cancer research

Increased investment in cancer research is driving significant advancements in the development of research antibodies and reagents, which are essential tools for understanding and targeting cancer at the molecular level. As cancer research continues to evolve, funding has allowed scientists to develop more specific, sensitive, and diverse antibodies, enhancing their ability to detect cancer markers and track tumor progression. These reagents are critical in both basic research and clinical settings, facilitating a deeper understanding of cancer biology, identifying new therapeutic targets, and improving diagnostics. The growing focus on immunotherapy and personalized medicine has further fueled the demand for high-quality antibodies, which can target specific cancer cells while minimizing damage to healthy tissue.

Threat:

Quality and specificity issues

The research antibodies and reagents market is facing significant challenges related to quality and specificity issues, which are hampering their effectiveness in scientific studies. Antibodies, crucial for detecting and analyzing proteins, often suffer from inconsistency in performance due to variations in manufacturing processes and inadequate validation. This results in poor reproducibility, where antibodies may bind to unintended targets, leading to inaccurate results. The lack of standardization in reagent formulations complicates experimental protocols, as researchers may face difficulty replicating results across different laboratories.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the research antibodies and reagents market, disrupting supply chains, research priorities, and manufacturing processes. During the height of the pandemic, many laboratories and research institutions shifted focus toward studying the virus, which led to an increased demand for antibodies, reagents, and diagnostic tools specific to COVID-19 detection and treatment. This situation forced many researchers to adapt by sourcing alternative reagents or modifying their research protocols. Despite these challenges, the pandemic also accelerated innovations in antibody and reagent development, especially for virus detection and vaccine research, which will likely have lasting benefits for future immunological studies and diagnostics.

The Flow Cytometry segment is expected to be the largest during the forecast period

Flow Cytometry segment is expected to dominate the largest share over the estimated period. Flow cytometry is a powerful tool used in immunology, cell biology, and diagnostics to analyze and sort cells based on their physical and chemical properties. The segment focused on enhancing research antibodies and reagents is crucial for improving the precision and reliability of flow cytometry techniques. By developing highly specific and optimized antibodies, researchers can target a wide range of cell surface markers and intracellular proteins, facilitating the study of complex biological processes. Innovations in reagents, such as fluorescence conjugates, buffers, and detection systems, further enhance the sensitivity, resolution, and accuracy of flow cytometry.

The Drug Development segment is expected to have the highest CAGR during the forecast period

Drug Development segment is estimated to grow at a rapid pace during the forecast period. The drug development sector is increasingly focusing on enhancing research antibodies and reagents to accelerate the discovery and development of new therapeutics. These antibodies and reagents play a critical role in understanding the underlying mechanisms of diseases, identifying potential drug targets, and validating therapeutic candidates. By improving the quality, specificity, and reliability of these tools, researchers can generate more accurate and reproducible data, which is essential for advancing drug discovery. Enhanced research antibodies help in precise biomarker detection, cell signaling pathway analysis and in vitro diagnostic applications.

Region with largest share:

North America region is poised to hold the largest share of the market throughout the extrapolated period. With continuous advancements in biotechnology, pharmaceuticals, and personalized medicine, the demand for high-quality antibodies and reagents has surged. These tools are crucial for the development of targeted therapies, biomarker identification, and diagnostics, especially in cancer, autoimmune diseases, and infectious diseases. North American researchers are leveraging cutting-edge techniques such as CRISPR and gene editing, which rely heavily on specialized reagents and antibodies. Additionally, increasing investment in research and development by pharmaceutical companies and academic institutions is further accelerating the demand across the region.

Region with highest CAGR:

Europe region is estimated to witness the highest CAGR during the projected time frame. By fostering collaborations between academic institutions, research organizations, and biotechnology companies, Europe has become a hub for cutting-edge developments in life sciences. These partnerships enable the sharing of expertise, resources, and technologies, which accelerates the discovery and optimization of high-quality antibodies and reagents. Additionally, joint ventures and collaborations with global industry leaders ensure access to the latest technologies and regulatory insights, promoting the development of more specific and effective research tools. As a result, European researchers benefit from a wider array of specialized products, enhancing their ability to conduct precise and impactful experiments.

Key players in the market

Some of the key players in Research Antibodies and Reagents market include Abcam Limited, Agilent Technologies, Inc, Bio-Rad Laboratories, Inc, F. Hoffmann-La Roche AG, GE Healthcare Life Sciences, Merck Group, OriGene Technologies, PerkinElmer, Promega Corporation, SAB Biotherapeutics, Santa Cruz Biotechnology, Tecan Group, Thermo Fisher Scientific, Eppendorf AG and Lonza Group.

Key Developments:

In August 2023, Danaher (US) entered into a definitive agreement to acquire all the outstanding shares of Abcam plc (UK). Through this development, Abcam is expected to operate as a standalone operating company within Danaher's Life Sciences segment.

In August 2023, Agilent Technologies, Inc. (US) announced the opening of a new full-scale Integrated Biology Center located at Monash University in Malaysia. The facility is focused on building local capabilities to accelerate research and development (R&D) in life science research.

Technologies Covered:

  • Flow Cytometry
  • Immunoprecipitation
  • Western Blotting
  • Multiplex Immunosorbent Assay
  • Enzyme-Linked Immunosorbent Assay
  • Other Technologies

Applications Covered:

  • Drug Development
  • Proteomics
  • Genomics

End Users Covered:

  • Pharmaceutical and Biotechnologies Industries
  • Academic and Research Institutions
  • Contract Research Organizations

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Research Antibodies and Reagents Market, By Technology

  • 5.1 Introduction
  • 5.2 Flow Cytometry
  • 5.3 Immunoprecipitation
  • 5.4 Western Blotting
  • 5.5 Multiplex Immunosorbent Assay
  • 5.6 Enzyme-Linked Immunosorbent Assay
  • 5.7 Other Technologies

6 Global Research Antibodies and Reagents Market, By Application

  • 6.1 Introduction
  • 6.2 Drug Development
  • 6.3 Proteomics
  • 6.4 Genomics

7 Global Research Antibodies and Reagents Market, By End User

  • 7.1 Introduction
  • 7.2 Pharmaceutical and Biotechnologies Industries
  • 7.3 Academic and Research Institutions
  • 7.4 Contract Research Organizations

8 Global Research Antibodies and Reagents Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Abcam Limited
  • 10.2 Agilent Technologies, Inc
  • 10.3 Bio-Rad Laboratories, Inc
  • 10.4 F. Hoffmann-La Roche AG
  • 10.5 GE Healthcare Life Sciences
  • 10.6 Merck Group
  • 10.7 OriGene Technologies
  • 10.8 PerkinElmer
  • 10.9 Promega Corporation
  • 10.10 SAB Biotherapeutics
  • 10.11 Santa Cruz Biotechnology
  • 10.12 Tecan Group
  • 10.13 Thermo Fisher Scientific
  • 10.14 Eppendorf AG
  • 10.15 Lonza Group